No genetic alteration, including KRAS-mutant allele frequency or STK11 mutation status, was able to predict the anti-tumour activity, although baseline gene/protein expression of members of the HER family of receptor tyrosine kinase did exhibit a trend with the degree of anti-tumour response. The gene discussed is NTRK1; the disease is neoplasm.